Total Valuation
Biogen has a market cap or net worth of €26.00B. The enterprise value is €39.20K.
Market Cap€26.00B
Enterprise Value€39.20K
Share Statistics
Biogen has 147,754,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding147,754,000
Owned by Insiders0.18%
Owned by Institutions3.69%
Financial Efficiency
Biogen’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 6.62%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)6.62%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.31M
Profits Per Employee172.39K
Employee Count7,500
Asset Turnover0.33
Inventory Turnover1.34
Valuation Ratios
The current PE Ratio of Biogen is 35.7. Biogen’s PEG ratio is -0.95.
PE Ratio35.7
PS Ratio2.63
PB Ratio1.41
Price to Fair Value1.41
Price to FCF12.59
Price to Operating Cash Flow10.67
PEG Ratio-0.95
Income Statement
In the last 12 months, Biogen had revenue of 9.81B and earned 1.29B in profits. Earnings per share was 8.85.
Revenue9.81B
Gross Profit6.91B
Operating Income1.88B
Pretax Income1.40B
Net Income1.29B
EBITDA3.10B
Earnings Per Share (EPS)8.85
Cash Flow
In the last 12 months, operating cash flow was 2.88B and capital expenditures 89.80M, giving a free cash flow of 2.97B billion.
Operating Cash Flow2.88B
Free Cash Flow2.97B
Free Cash Flow per Share20.09
Dividends & Yields
Biogen pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change59.53%
50-Day Moving Average176.32
200-Day Moving Average158.71
Relative Strength Index (RSI)48.87
Average Volume (3m)31.00
Important Dates
Biogen upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).
Last Earnings DateJul 29, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Biogen as a current ratio of 2.68, with Debt / Equity ratio of 44.33%
Current Ratio2.68
Quick Ratio2.03
Debt to Market Cap0.26
Net Debt to EBITDA1.27
Interest Coverage Ratio7.63
Taxes
In the past 12 months, Biogen has paid 108.11M in taxes.
Income Tax108.11M
Effective Tax Rate0.08
Enterprise Valuation
Biogen EV to EBITDA ratio is 9.60, with an EV/FCF ratio of 14.51.
EV to Sales3.03
EV to EBITDA9.60
EV to Free Cash Flow14.51
EV to Operating Cash Flow13.50
Balance Sheet
Biogen has €1.28B in cash and marketable securities with €8.36B in debt, giving a net cash position of -€7.07B billion.
Cash & Marketable Securities€1.28B
Total Debt€8.36B
Net Cash-€7.07B
Net Cash Per Share-€47.85
Tangible Book Value Per Share€17.64
Margins
Gross margin is 67.71%, with operating margin of 19.14%, and net profit margin of 13.18%.
Gross Margin67.71%
Operating Margin19.14%
Pretax Margin14.29%
Net Profit Margin13.18%
EBITDA Margin31.60%
EBIT Margin22.07%
Analyst Forecast
The average price target for Biogen is €202.34, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€202.34
Price Target Upside13.66% Upside
Analyst ConsensusModerate Buy
Analyst Count28
Revenue Growth Forecast-6.22%
EPS Growth Forecast-49.01%